Psoriasis
Drug research and approvals for psoriasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 211 studies of psoriasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 163 drug trials for it since 2013, FDA has 2 approved and 2 open orphan designations naming it, and the EU has 20 authorised medicines for it.
- Recruiting worldwide: 211
- Trials authorized in Canada: 163
- FDA orphan approvals: 2
- EU medicines: 20
Recruiting Now
Newest start dates first, of 211 recruiting on ClinicalTrials.gov ↗- A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)NCT07850310 · Phase 1 · Merck Sharp & Dohme LLC · starts Oct 20, 2026
- A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic…NCT07801495 · Phase 2 · Novartis Pharmaceuticals · starts Oct 19, 2026
- A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of…NCT07802964 · Phase 1 · Fujian Shengdi Pharmaceutical Co., Ltd. · starts Sep 21, 2026
- An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail PsoriasisNCT07725822 · Phase 4 · Modern Research Associates, PLLC · starts Sep 15, 2026
- A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical…NCT07746583 · Not reported · Janssen-Cilag Kft. · starts Sep 3, 2026
- A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque PsoriasisNCT07724366 · Phase 3 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · starts Sep 2, 2026
- Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control…NCT07858591 · Not reported · Bursa Yuksek Ihtisas Training and Research Hospital · starts Sep 1, 2026
- Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory ArthritisNCT07460739 · Not applicable · Assistance Publique - Hôpitaux de Paris · starts Aug 31, 2026
- A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving…NCT07654751 · Phase 4 · Janssen Research & Development, LLC · starts Aug 7, 2026
- A Study of HL40626S Tablets in Healthy AdultsNCT07736586 · Phase 1 · HighsLab Therapeutics Inc. · starts Aug 5, 2026
Trials Authorized in Canada
The 10 newest of 163; search them all in Canada trials| Apr 8, 2026 | An open-label study with maintenance dosing to evaluate the long-term safety, tolerability, and efficacy of orka-002 in participants with moderate-to-severe…ORKA-002 | ORUKA THERAPEUTICS, INC. | Ongoing |
| Feb 12, 2026 | An open-label extension study to evaluate the long-term safety, tolerability, and efficacy of orka-001 in participants with moderate-to-severe plaque psoriasisORKA-001 | ORUKA THERAPEUTICS, INC. | Ongoing |
| Dec 16, 2025 | A multicenter, randomized, double-blinded, placebo-controlled dose-range finding study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of…ORKA-002 | ORUKA THERAPEUTICS, INC. | Ongoing |
| Dec 11, 2025 | Multicenter, randomized, double-blinded, placebo controlled, dose-range finding study of orka-001 in participants with moderate-to-severe plaque psoriasisORKA-001 | ORUKA THERAPEUTICS, INC. | Ongoing |
| Sep 19, 2025 | A phase 3b/4 multi-center, randomized, open-label, long-term safety study of deucravacitinib in comparison to ustekinumab in participants with…DEUCRAVACITINIB (BMS-986165) | Bristol-Myers Squibb | Ongoing |
| Jul 16, 2025 | A multicenter, randomized, double-blinded, placebo -controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of orka-001 in…ORKA-001 | ORUKA THERAPEUTICS, INC. | Ongoing |
| Jun 23, 2025 | A multicenter, randomized, double-blind, placebo-controlled phase 3study to evaluate the efficacy, safety and pharmacokinetics ofdeucravacitinib in adolescent…DEUCRAVACITINIB (BMS-986165) | Bristol-Myers Squibb | Ongoing |
| Jun 11, 2025 | A phase 3, randomized, multicenter, double-blind trial to evaluate the efficacy, safety, and tolerability of zasocitinib (tak-279) compared to deucravacitinib…ZASOCITINIB (TAK-279) / DEUCRAVACITINIB | Takeda Pharmaceuticals USA | Closed |
| Mar 28, 2025 | A phase 3 multicenter, randomized, double-blind, placebo-controlled and ustekinumab active comparator-controlled study to evaluate the efficacy and safety of…ICOTROKINRA (JNJ-77242113) / USTEKINUMAB | Johnson & Johnson | Ongoing |
| Jan 17, 2025 | An extension study in patients with moderate to severe plaque psoriasis to evaluate the long-term safety, efficacy, and durability of response to esk-001…ENVUDEUCITINIB (ESK-001) | ALUMIS INC. | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Mar 18, 2024 | Spevigotreatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg | LEO Pharma Inc. | Approved |
| Sep 1, 2022 | SpevigoTreatment of generalized pustular psoriasis (GPP) flares in adults | LEO Pharma Inc. | Approved |
| Oct 16, 2023 | Recombinant Humanized Anti-interleukin 36R Monoclonal…Treatment of generalized pustular psoriasis | Shanghai Huaota Biopharmaceutical Co., Ltd. | Designated |
| Jul 7, 2020 | imsidolimabTreatment of generalized pustular psoriasis | Vanda Pharmaceuticals Inc. | Designated |
Medicines Authorised in the EU
Newest first; 15 of 20| Sep 18, 2026 | Icotydeicotrokinra hydrochloride | Janssen-Cilag International | EMA ↗ |
| Sep 17, 2025 | Usrentyustekinumab · biosimilar | Biosimilar Collaborations Ireland Limited | EMA ↗ |
| Aug 14, 2025 | Usymroustekinumab · biosimilar | Gedeon Richter Plc. | EMA ↗ |
| Feb 14, 2025 | Yesintekustekinumab · biosimilar | Biosimilar Collaborations Ireland Limited | EMA ↗ |
| Sep 25, 2024 | Otulfiustekinumab · biosimilar | Fresenius Kabi Deutschland GmbH | EMA ↗ |
| Aug 22, 2024 | Steqeymaustekinumab · biosimilar | Celltrion Healthcare Hungary Kft. | EMA ↗ |
| Jun 20, 2024 | Wezenlaustekinumab · biosimilar | Amgen Technology (Ireland) UC | EMA ↗ |
| Jan 5, 2024 | Uzpruvoustekinumab · biosimilar | Stada Arzneimittel AG | EMA ↗ |
| Mar 24, 2023 | Sotyktudeucravacitinib | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Dec 9, 2022 | Spevigospesolimab | LEO Pharma A/S | EMA ↗ |
| Aug 20, 2021 | Bimzelxbimekizumab | UCB Pharma S.A. | EMA ↗ |
| Apr 26, 2019 | Skyrizirisankizumab | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Sep 17, 2018 | Ilumetritildrakizumab | Almirall, S.A. | EMA ↗ |
| May 18, 2018 | Zesslyinfliximab · biosimilar | Sandoz GmbH | EMA ↗ |
| Nov 10, 2017 | Tremfyaguselkumab | Janssen-Cilag International NV | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA